Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Capital Expenditures (2017 - 2024)

Solid Biosciences (SLDB) has disclosed Capital Expenditures for 8 consecutive years, with -$36000.0 as the latest value for Q4 2024.

  • Quarterly Capital Expenditures fell 147.37% to -$36000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $112000.0 through Sep 2024, up 106.86% year-over-year, with the annual reading at $46000.0 for FY2025, N/A changed from the prior year.
  • Capital Expenditures hit -$36000.0 in Q4 2024 for Solid Biosciences, down from $16000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q2 2022 to a low of -$1.6 million in Q4 2022.
  • Historically, Capital Expenditures has averaged $84526.3 across 5 years, with a median of $37000.0 in 2021.
  • Biggest five-year swings in Capital Expenditures: crashed 961.67% in 2021 and later soared 2754.05% in 2022.
  • Year by year, Capital Expenditures stood at $60000.0 in 2020, then plummeted by 961.67% to -$517000.0 in 2021, then plummeted by 215.67% to -$1.6 million in 2022, then surged by 104.66% to $76000.0 in 2023, then crashed by 147.37% to -$36000.0 in 2024.
  • Business Quant data shows Capital Expenditures for SLDB at -$36000.0 in Q4 2024, $16000.0 in Q3 2024, and $20000.0 in Q1 2024.